PHARMASPIRE - Volume 11, Issue 2, April - June, 2019
Pages: 51-62
Date of Publication: 14-Jun-2022
Print Article
Download XML Download PDF
Role of phosphoinositide-3-kinase/AKT activation mediated by inhibition of protein tyrosine phosphate-1B inhibitor in cardioprotection
Author: Shivani Verma, Himanshi Khera, Anupam Awasthi, Sidharth Mehan
Category: Pharmaceutics
Abstract:
Background: Dyslipidemia is a downregulator of phosphoinositide-3-kinase (PI3K)/AKT-mediated cell survival pathway and reduces the preconditioning potential in ischemic-reperfusion (I/R) injured rat heart ultimately leads to cardiac cell death. Objective: The present study was designed to explore and confirm the pharmacological perspective of sodium orthovanadate (SOV), an inhibitor of tyrosine phosphate-1B protein against ischemic-reperfusion (I/R) injury in dyslipidemic rat. Martials and Methods: The dyslipidemic rodent hearts were isolated and fixed on Langendorff’s device, exposed to 30 miniature reperfusion. Ischemic preconditioning was started by four episodes of 5 min ischemia and 5 min reperfusion. Infarction was assessed using triphenyltetrazolium chloride staining, and coronary effluent was inspected for lactate dehydrogenase (LDH) and creatinine kinase-MB discharge to decide the degree of myocardial damage. The cardiac discharge of nitric oxide (NO) was assessed by determining the discharge of nitrite in coronary emission. Results: Pharmacological preconditioning with SOV significantly re-imposed I/R mediated myocardial infarction in dyslipidemic rat heart when compared with dyslipidemic and I/R control group. In this study, the statistical data show the significant values P < 0.05. However, in observed results, cardioprotection was abolished by perfusion of BEZ-235, a PI3K/AKT pathway inhibitor noted in terms of myocardial injury events such as a rise in myocardial infarct mass, tumor necrosis factor-alpha, LDH, CK-MB, and also decrease in the release of NO. Conclusion: Hence, it stated that SOV repairs impaired cardioprotective effect in dyslipidemic rat heart maybe because of activation of the PI3K/AKT cell survival pathway which was confirmed using PI3K/AKT inhibitor BEZ-235.
Keywords: Dyslipidemia, ischemic reperfusion injury, ischemic preconditioning, phosphoinositide-3-kinase, protein kinase-B
References:
1. Forouzanfar MH, Moran AE, Flaxman AD, Roth G, Mensah GA, Ezzati M, et al. Assessing the global burden of ischemic heart disease, Part 2: Analytic methods and estimates of the global epidemiology of ischemic heart disease in 2010. Glob Heart 2012;7:331-42.
2. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: A report from the American heart association. Circulation 2017;135:e146-603.
3. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest 2013;123:92-100.
4. Beyersdorf F. The use of controlled reperfusion strategies in cardiac surgery to minimize ischaemia/reperfusion damage. Cardiovasc Res 2009;83:262-8.
5. Balakumar P, Rohilla A, Singh M. Pre-conditioning and postconditioning to limit ischemia-reperfusion-induced myocardial injury: What could be the next footstep? Pharmacol Res 2008;57:403-12.
6. Goyal A, Agrawal N. Ischemic preconditioning: Interruption of various disorders. J Saudi Heart Assoc 2017;29:116-27.
7. Mittal D, Taliyan R, Sharma PL, Yadav HN. Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart. Indian J Pharmacol 2016;48:59-63.
8. Yang C, Talukder MH, Varadharaj S, Velayutham M, Zweier JL. Early ischaemic preconditioning requires Akt-and PKA-mediated activation of eNOS via serine1176 phosphorylation. Cardiovasc Res 2013;97:33-43.
9. Kodjebacheva G, Inoue S, Scherrer T, Rice G, Grigorian M, Blankenship J, et al. Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: A feasibility study. Int J Hematol 2016;104:200-7.
10. Björnsson B, Winbladh A, Bojmar L, Sundqvist T, Gullstrand P, Sandström P. Conventional, but not remote ischemic preconditioning, reduces iNOS transcription in liver ischemia/reperfusion. World J Gastroenterol 2014;20:9506-12.
11. Inoue S, Kodjebacheva G, Scherrer T, Rice G, Grigorian M, Blankenship J, et al. Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: A feasibility study. Int J Hematol 2016;104:200-7.
12. Luiking YC, Engelen MP, Deutz NE. Regulation of nitric oxide production in health and disease. Curr Opin Clin Nutr Metab Care 2010;13:97-104.
13. Shvedova M, Anfinogenova Y, Popov SV, Atochin DN. Connexins and nitric oxide inside and outside mitochondria: Significance for cardiac protection and adaptation. Front Physiol 2018;9:1-13.
14. Mahmoud AM, Wilkinson FL, McCarthy EM, Moreno-Martinez D, LangfordSmith A, Romero M, et al. Endothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress. FASEB J 2017;31:4636-48.
15. Devallière J, Charreau B. The adaptor lnk (SH2B3): An emerging regulator in vascular cells and a link between immune and inflammatory signaling. Biochem Pharmacol 2011;82:1391-402.
16. Mack AK, Kato GJ. Sickle cell disease and nitric oxide: A paradigm shift? Int J Biochem Cell Biol 2006;38:1237-43.
17. Piccin A, Murphy C, Eakins E, Rondinelli MB, Daves M, Vecchiato C, et al. Insight into the complex pathophysiology of sickle cell anaemia and possible treatment. Eur J Haematol 2019;102:319-30.
18. Kajiume T, Yoshimi S, Nagita A, Kobayashi K, Kataoka N. Application of nitric oxide for a case of veno-occlusive disease after peripheral blood stem cell transplantation. Pediatr Hematol Oncol 2000;17:601-4.
19. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma 2002;2:S35-9.
20. Safar ME, Gnakaméné JB, Bahous SA, Yannoutsos A, Thomas F. Longitudinal study of hypertensive subjects with Type 2 diabetes mellitus: Overall and cardiovascular risk. Hypertension 2017;69:1029-35.
21. Turer AT, Hill JA. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010;106:360-8.
22. Fan G, Aleem S, Yang M, Miller WT, Tonks NK. Protein tyrosine phosphatase and kinase specificity in regulation of SRC and BRK. J Biol Chem 2015;290:15934-47.
23. Knobler H, Elson A. Metabolic regulation by protein tyrosine phosphatases. J Biomed Res 2014;28:157-68.
24. Panzhinskiy E, Ren J, Nair S. Protein tyrosine phosphatase 1B and insulin resistance: Role of endoplasmic reticulum stress/reactive oxygen species/ nuclear factor kappa B axis. PLoS One 2013;8:e77228.
25. Liu X, Wu X, Cai L, Tang C, Su J. Hypoxic preconditioning of cardiomyocytes and cardioprotection: Phophorylation of HIF-1alpha induced by p42/p44 mitogen-activated protein kinases is involved. Pathophysiology 2003;9:201-5.
26. Takada Y, Hashimoto M, Kasahara J, Aihara K, Fukunaga K. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis. J Pharmacol Exp Ther 2004;311:1249-55.
27. Kim CH, Hao J, Ahn HY, Kim SW. Activation of Akt/protein kinase B mediates the protective effects of mechanical stretching against myocardial ischemiareperfusion injury. J Vet Sci 2012;13:235-44.
28. Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, et al. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 2007;102:163.
29. Moor VJ, Amougou SN, Ombotto S, Ntone F, Wouamba DE, Nonga BN. Dyslipidemia in patients with a cardiovascular risk and disease at the university teaching hospital of Yaoundé, Cameroon. Int J Vasc Med 2017;2017:6061306.
30. Navar-Boggan AM, Peterson ED, D’Agostino RB Sr., Neely B, Sniderman AD, Pencina MJ. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 2015;131:451-8.
31. Rubin C, Gal GU, Yarden Y. Negative regulation of receptor tyrosine kinases: Unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 2005;15:66-71.
32. Elserafy AS, Okasha N, Hegazy T. Prevention of contrast induced nephropathy by ischemic preconditioning in patients undergoing percutaneous coronary angiography. Egypt Heart J 2018;70:107-111.
33. Yadav HN, Singh M, Sharma PL. Modulation of the cardioprotective effect of ischemic preconditioning in hyperlipidaemic rat heart. Eur J Pharmacol 2010;643:78-83.
34. Skrzypiec-Spring M, Grotthus B, Szel?g A, Schulz R. Isolated heart perfusion according to langendorff-still viable in the new millennium. J Pharmacol Toxicol Methods 2007;55:113-26.
36. Cimino S, Canali E, Petronilli V, Cicogna F, De Luca L, Francone M, et al. Global and regional longitudinal strain assessed by two-dimensional speckle tracking echocardiography identifies early myocardial dysfunction and transmural extent of myocardial scar in patients with acute ST elevation myocardial infarction and relatively preserved LV function. Eur Heart J Cardiovasc Imaging 2012;14:805-11.
37. Kumar KA, Maheswari MU, Sivashanmugam AT, Devi VS, Subhashini N, RaviTK. Free radical scavenging and antioxidant activities of Glinus oppositifolius (carpet weed) using different in vitro assay systems. Pharm Biol 2009;47:474-82.
38. Yellon DM, Hausenloy DJ. Realizing the clinical potential of ischemic preconditioning and postconditioning. Nat Clin Pract Cardiovasc Med 2005;2:568-75.
39. Gupta V, Goyal R, Sharma PL. Preconditioning offers cardioprotection in hyperlipidemic rat hearts: Possible role of dopamine (D2) signaling. BMC Cardiovasc Disord 2015;15:77-85.
40. Gou SH, Huang HF, Chen XY, Liu J, He M, Ma YY, et al. Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture hong-qu and gypenosides in hyperlipidemia with NAFLD rats. J Chin Med Assoc 2016;79:111-21.
41. Kunecki M, P?azak W, Podolec P, Go?ba KS. Effects of endogenous cardioprotective mechanisms on ischemia-reperfusion injury. Postepy Hig Med Dosw (Online) 2017;71:20-31. 42. Rubino A, Yellon DM. Ischaemic preconditioning of the vasculature: An overlooked phenomenon for protecting the heart? Trends Pharmacol Sci 2000;21:225-30.
43. Heusch G. Molecular basis of cardioprotection: Signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 2015;116:674-99.
44. Santhanam AV, d’Uscio LV, Smith LA, Katusic ZS. Uncoupling of eNOS causes superoxide anion production and impairs NO signaling in the cerebral microvessels of hph-1 mice. J Neurochem 2012;122:1211-8.
45. Kansal SK, Jyoti U, Sharma S, Kaura A, Deshmukh R, Goyal S. Effect of zinc supplements in the attenuated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart. Naunyn Schmiedebergs Arch Pharmacol 2015;388:635-41.
46. Rana A, Sharma S. Mechanism of sphingosine?1?phosphate induced cardioprotection against I/R injury in diabetic rat heart: Possible involvement of glycogen synthase kinase 3β and mitochondrial permeability transition pore. Clin Exp Pharmacol Physiol 2016;43:166-73.
47. Basavarajappa DK, Gupta VK, Rajala RV. Protein tyrosine phosphatase 1B: A novel molecular target for retinal degenerative diseases. Adv Exp Med Biol 2012;723:829-34.
48. Piccin A, Steurer M, Feistritzer C, Murphy C, Eakins E, Van Schilfgaarde M, et al. Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Transl Res 2017;184:21-34.
49. Chen C, Cao M, Zhu S, Wang C, Liang F, Yan L, et al. Discovery of a novel inhibitor of the protein tyrosine phosphatase Shp2. Sci Rep 2015;5:17626-39.
50. Youn YJ, Yoo BS, Son JW, Lee JW, Ahn MS, Ahn SG, et al. Remote ischemic conditioning by effluent collected from a novel isolated hindlimb model reduces infarct size in an isolated heart model. Korean Circ J 2017;47:714-26.
51. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53:2079-86.
52. Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, Mukhametshina RT, Kwek XY, Cabrera-Fuentes HA, et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther 2018;186:73-87.
|
